Skip to main content
Trials
Sponsors
Conditions
Drugs
Pricing
Trials
Sponsors
Conditions
Drugs
Pricing
Loading search results
Clinical Trials for "Li Li, MD"
22
trials
Share
Relevance
ID
Status
Phase
Title
Sponsor
NCT00341653
Completed
A Cohort Study of Smoking Prevention and Health Promotion for Middle School Students in Wuhan, China
National Institute of Environmental Health Sciences (NIEHS)
ClinicalTrials.gov
NCT00341653
Completed
-
A Cohort Study of Smoking Prevention and Health Promotion for Middle School Stud...
National Institute of Env...
NCT01912027
Unknown
Not Applicable
Open Latarjet Techniques Versus Arthroscopic Latarjet Techniques on Anterior Shoulder Instability: The Comparison of Clinical and Radiographic Outcomes
Fenglong Li, MD
ClinicalTrials.gov
NCT01912027
Unknown
Not Applicable
Open Latarjet Techniques Versus Arthroscopic Latarjet Techniques on Anterior Sho...
Fenglong Li, MD
NCT02336997
Unknown
Phase 1/2
Evaluation of the Effect of Autologous Fat and SVF Transplantation in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration
Qing-FengLi Li,MD
ClinicalTrials.gov
NCT02336997
Unknown
Phase 1/2
Evaluation of the Effect of Autologous Fat and SVF Transplantation in Promoting...
Qing-FengLi Li,MD
NCT02426931
Unknown
Not Applicable
Tip-flexible Semi-rigid Ureterorenoscope Versus Flexible Ureteroscopy in Renal Calculi
Beijing Tsinghua Changgeng Hospital
ClinicalTrials.gov
NCT02426931
Unknown
Not Applicable
Tip-flexible Semi-rigid Ureterorenoscope Versus Flexible Ureteroscopy in Renal C...
Beijing Tsinghua Changgen...
NCT03434210
Unknown
Not Applicable
The Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia
Yi Li MD, PhD
ClinicalTrials.gov
NCT03434210
Unknown
Not Applicable
The Effect of a Community-based LAT-treated Management Model on the Violence Ris...
Yi Li MD, PhD
NCT04230447
Recruiting
Establishment of a Cohort of Patients With Sepsis-associated Encephalopathy (SAE)
Yi Li, MD
ClinicalTrials.gov
NCT04230447
Recruiting
-
Establishment of a Cohort of Patients With Sepsis-associated Encephalopathy (SAE...
Yi Li, MD
NCT05157542
Unknown
Phase 1
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC
Juan LI, MD
ClinicalTrials.gov
NCT05157542
Unknown
Phase 1
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NS...
Juan LI, MD
NCT06192849
Recruiting
Phase 2
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Juan LI, MD
ClinicalTrials.gov
NCT06192849
Recruiting
Phase 2
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Gr...
Juan LI, MD
NCT06256289
Unknown
Phase 4
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
Ping Li,MD
ClinicalTrials.gov
NCT06256289
Unknown
Phase 4
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndro...
Ping Li,MD
NCT07369882
Recruiting
Not Applicable
Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Qunxing Li,MD
ClinicalTrials.gov
NCT07369882
Recruiting
Not Applicable
Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After N...
Qunxing Li,MD
NCT07371611
Recruiting
Phase 3
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
Qunxing Li,MD
ClinicalTrials.gov
NCT07371611
Recruiting
Phase 3
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally A...
Qunxing Li,MD
NCT04459663
Unknown
Phase 2
JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.
Li Zhang, MD
ClinicalTrials.gov
NCT04459663
Unknown
Phase 2
JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemot...
Li Zhang, MD
NCT04695925
Active Not Recruiting
Phase 3
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
Cancer Hospital of Guangxi Medical University
ClinicalTrials.gov
NCT04695925
Active Not Recruiting
Phase 3
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Conc...
Cancer Hospital of Guangx...
NCT05003037
Active Not Recruiting
Phase 2
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
Li Zhang, MD
ClinicalTrials.gov
NCT05003037
Active Not Recruiting
Phase 2
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-S...
Li Zhang, MD
NCT05178511
Unknown
Phase 2
Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance
Li Zhang, MD
ClinicalTrials.gov
NCT05178511
Unknown
Phase 2
Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK...
Li Zhang, MD
NCT05245994
Unknown
Phase 2
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Li Zhang, MD
ClinicalTrials.gov
NCT05245994
Unknown
Phase 2
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as...
Li Zhang, MD
NCT05901974
Recruiting
Phase 2
Venetoclax Combined With Azactidine in the Treatment of ALAL
Affiliated Hospital of Nantong University
ClinicalTrials.gov
NCT05901974
Recruiting
Phase 2
Venetoclax Combined With Azactidine in the Treatment of ALAL
Affiliated Hospital of Na...
NCT05940961
Recruiting
Phase 2
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Affiliated Hospital of Nantong University
ClinicalTrials.gov
NCT05940961
Recruiting
Phase 2
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Affiliated Hospital of Na...
NCT06798948
Recruiting
Phase 2
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Li Lab,MD
ClinicalTrials.gov
NCT06798948
Recruiting
Phase 2
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma...
Li Lab,MD
NCT07632222
Not Yet Recruiting
Phase 1/2
High-Protein Diet for Improving Alcoholic Fatty Liver Disease
Harbin Medical University
ClinicalTrials.gov
NCT07632222
Not Yet Recruiting
Phase 1/2
High-Protein Diet for Improving Alcoholic Fatty Liver Disease
Harbin Medical University
Result Breakdown
Status
Unknown
9 (45%)
Recruiting
7 (35%)
Active, not recruiting
2 (10%)
Completed
1 (5%)
Not yet recruiting
1 (5%)
Phase
Phase 2
8 (40%)
not_applicable
4 (20%)
Not Specified
2 (10%)
Phase 1/2
2 (10%)
Phase 3
2 (10%)
Phase 1
1 (5%)
Phase 4
1 (5%)
Top Conditions
Non Small Cell Lung Cancer
2 (10%)
Asthma
1 (5%)
Shoulder Instability
1 (5%)
Show 7 more
Top Sponsors
Li Zhang, MD
5 (25%)
Juan LI, MD
2 (10%)
Qunxing Li,MD
2 (10%)
Show 7 more
Start your search
Search over 500,000 clinical trials worldwide
Search
Expert
Popular:
Cancer
Diabetes
Alzheimer
COVID-19
Heart Disease